drugset / Trial / NCT02080234
Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of first-line gemcitabine, oxaliplatin, and asparaginase (GELOX) with concurrent involved-field radiation therapy for patients in newly diagnosed stage IE/IIE ENKTL.
Timeline
- Start
- 2014-03
- Primary completion
- 2016-12
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 iu | Intramuscular |